Plomestane

Plomestane (INN, USAN) (former developmental code name MDL-18,962), also known as propargylestrenedione (PED), as well as 10-propargylestr-4-ene-3,17-dione, is a steroidal, irreversible aromatase inhibitor which was under development by Marion Merrell Dow/Hoechst Marion Russell (now Hoechst AG) as an antineoplastic agent for the treatment of breast cancer. It was found to be effective in preclinical studies and was also found to produce few adverse effects in human clinical trials, significantly reducing estrogen levels with a single administration. However, development of the drug for clinical use was halted due to "technical issues" and it was never marketed.

In addition to its activity as an aromatase inhibitor, plomestane has weak androgenic properties.